Malignancy highlights from ASH 2012, Atlanta
The American Society of Hematology (ASH) 54th Annual Meeting was held on 8-11 December 2012. In the following four short films, Finbarr Cotter (Barts Cancer Institute, London, and Editor-in-Chief of the British Journal of Haematology) is joined in Atlanta by experts in haematological malignancy to discuss their presentations and highlights from the conference. The films focus on the areas of lymphoma, myeloma, the GAUDI study and chronic lymphocytic leukaemia (CLL), including new trial data on treatment in the elderly.
Click on the thumbnails below to view the films
Andrew Davies (Southampton General Hospital) and Andrew Evens (University of Massachusetts Medical School) discuss their presentations on new lymphoma trials, and John Gribben (Barts Cancer Institute, London) summarises his overall highlights from the meeting.
Paul Richardson (Dana-Farber Cancer Institute, Boston) and Graham Jackson (Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne) discuss their presentations on new myeloma trials, along with other new compounds that are finding their place in the clinic for myeloma.
The GAUDI study
Martin Dyer (University of Leicester) discusses the results of the GAUDI study with the new humanised anti-CD20 antibody, which he presented at the ASH conference.
CLL treatment in the elderly
Stephen Mulligan (University of Sydney) discusses his presentation on the treatment of elderly patients with chronic lymphocytic leukaemia (CLL), an important study in an age group that represents the majority of real CLL patients.
This resource has been supported by a grant from Roche Products Limited. The resource has been independently created and Roche Products have had no input into the content.